A method for detecting vitamin B1 impurities
Through high-performance liquid chromatography detection and gradient elution technology, the detection method of vitamin B1 impurities was optimized, and the problem of poor separation of impurities in the EP pharmacopoeia was solved, and the effective separation of multiple impurities and the reliability of detection results was achieved.
Patent Information
- Application Number
- CN202111473256.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-12-02
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2041-12-02
AI Technical Summary
The existing vitamin B1 impurity detection method cannot effectively separate more than 10 impurities in the EP pharmacopoeia, and there are problems such as overlap between the main components and the impurities and the separation degree does not meet the requirements.
Using high-performance liquid chromatography detection method, octadecylsilane bonded silica gel column was used, and the mobile phase included hexane sulfonate solution and methanol solution. The volume fraction and pH of the mobile phase were adjusted through gradient elution technology, and combined with dilution. The use of agents is optimized to achieve separation of multiple impurities.
The effective separation of various impurities in vitamin B1 raw materials is achieved, the sensitivity and accuracy of detection is improved, and the reliability of the quality of the preparation is ensured.
Smart Images

Figure CN114295736B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of vitamin B1 impurity detection, and particularly relates to a method for detecting vitamin B1 impurities. Background Art
[0002] Vitamin B1, chemical name is 4-methyl-3-[(2-methyl-4-amino-5-pyrimidinyl)methyl]-5-(2-hydroxyethyl)thiazolium chloride hydrochloride, the compound structure is:
[0003]
[0004] This product is a vitamin drug. It combines with pyrophosphate in the body to form a coenzyme. It participates in the oxidative decarboxylation reaction of pyruvate and α-ketoglutaric acid in sugar metabolism and is necessary for sugar metabolism. When it is deficient, oxidation is blocked to form pyruvate, lactic acid accumulates, and affects the body's energy supply. Its symptoms are mainly manifested in the nervous and cardiovascular systems, and multiple peripheral neuritis affecting both sensory nerves and motor nerves occurs, manifested as paresthesia, neuralgia, limb weakness, muscle soreness and atrophy. In terms of cardiovascular, due to the increase of acetone and lactic acid in the blood, the small arteries are dilated, the diastolic pressure is reduced, and the myocardial metabolism is disordered, so it is easy to have symptoms of heart failure such as palpitations, shortness of breath, chest tightness, cardiac hypertrophy, liver and lung congestion and peripheral edema. In terms of the digestive tract, it is manifested as weakness and weight loss caused by decreased appetite.
[0005] Vitamin B1 was first discovered by Christiaan Eijkman and Gerrit Grijns in 1907. In the 20th century, American chemists Robert Williams, Waterman and Bookman extracted and isolated it from rice bran, named it thiamine, determined its chemical structure, and designed a synthesis method.
[0006] Related substances are one of the important quality control points for drug safety. Vitamin B1 is included in ChP2020 (Chinese Pharmacopoeia), USP44 (United States Pharmacopoeia), BP2021 (British Pharmacopoeia) / EP10.5 (European Pharmacopoeia), and JP17 (Japanese Pharmacopoeia). As for general impurities, the methods for related substances of vitamin B1 included in the pharmacopoeias of various countries are all elution systems of ion pair reagents and methanol acetonitrile. In the early stage of method establishment, the two methods of ChP2020 and BP2019 / EP10.5 were reproduced, and it was found that impurity H was not eluted in the detection method of related substances of vitamin B1 raw materials in ChP2020, and the peak shape of impurity A in the BP method was poor, with a shoulder peak, impurity 3 overlapped with the main component, and the impurities after the main peak were densely distributed, and the separation did not meet the requirements.
[0007] Therefore, it is necessary to further optimize the existing impurity detection method to achieve the effective separation of more than 10 impurities including EP pharmacopoeia impurities. Summary of the invention
[0008] The object of the present invention is to provide a method for detecting vitamin B1 impurities, which can effectively separate more than 10 impurities including EP pharmacopoeia impurities.
[0009] A method for detecting vitamin B1 impurities comprises performing high performance liquid chromatography on a sample to be detected, wherein the conditions include: a chromatographic column is an octadecylsilane bonded silica gel column; a UV detector wavelength is 243nm-249nm; a column temperature is 25°C-50°C; a mobile phase flow rate is 0.7-1.3mL / min; an injection volume is 10-50μL; the mobile phase comprises a mobile phase A and a mobile phase B, wherein the mobile phase A is a hexane sulfonate solution; the mobile phase B is a methanol solution; the elution mode is a gradient elution; and the diluent is a mobile phase A-mobile phase B mixed solution.
[0010] According to an embodiment of the present invention, the impurities include one or more of impurity A, impurity 2, impurity P, impurity 1, impurity B, impurity 3, impurity D, impurity F, impurity E, impurity G, impurity L, impurity C, o-chloroaniline and impurity H.
[0011] As preferred embodiments of the present invention, the impurities are impurity A, impurity 2, impurity P, impurity 1, impurity B, impurity 3, impurity D, impurity F, impurity E, impurity G, impurity L, impurity C, o-chloroaniline and impurity H.
[0012] According to an embodiment of the present invention, the detection wavelength of the high performance liquid chromatography detection is 245 nm.
[0013] According to an embodiment of the present invention, the hexane sulfonate solution used in the mobile phase A contains hexane sulfonate ions, phosphate ions, amino ions and alkali metal ions.
[0014] According to an embodiment of the present invention, the hexane sulfonate solution comprises sodium hexane sulfonate, triethylamine and phosphoric acid. Preferably, the concentration of the sodium hexane sulfonate is 0.01-0.03 mol / L, the concentration of the triethylamine is 0.1%-1.0%, and the pH value of the sodium hexane sulfonate solution is 3.2.
[0015] According to an embodiment of the present invention, the model of the chromatographic column is Kromasil KR100-5-C18, the size is 4.6 mm×250 mm, and the particle size is 3 μm or 5 μm.
[0016] According to an embodiment of the present invention, during the gradient elution process, based on the total volume of mobile phase A and mobile phase B, the volume fractions of the hexane sulfonate solution and methanol are as follows:
[0017] 0-20min: hexane sulfonate 95-99%, methanol 1-5%;
[0018] 20-50min: hexane sulfonate 88-92%, methanol 8-12%;
[0019] 50-70min: hexane sulfonate 73-77%, methanol 23-27%;
[0020] 70-80min: hexane sulfonate 48-52%, methanol 48-52%;
[0021] 80~80.1min: hexane sulfonate 48~52%, methanol 48~52%;
[0022] 80.1~105min: hexane sulfonate 95~99%, methanol 1~5%;
[0023] Above 105min: hexane sulfonate 95-99%, methanol 1-5%.
[0024] According to an embodiment of the present invention, the procedure of the gradient elution is:
[0025] 0-20min: mobile phase A 97%, mobile phase B 3%;
[0026] 20-50min: mobile phase A 90%, mobile phase B 10%;
[0027] 50-70min: mobile phase A 75%, mobile phase B 25%;
[0028] 70-80min: mobile phase A 50%, mobile phase B 50%;
[0029] 80~80.1min: mobile phase A 50%, mobile phase B 50%;
[0030] 80.1-105min: mobile phase A 97%, mobile phase B 3%;
[0031] More than 105 min: Mobile phase A 97%, mobile phase B 3%.
[0032] Compared with the prior art, the beneficial effects of the present invention are at least:
[0033] The method provided by the present invention can achieve effective separation between the main component and known impurities, as well as multiple unknown impurities. The methodological verification results such as specificity and sensitivity show that the method provided by the present invention has high sensitivity, good accuracy and good reproducibility, and can perform qualitative and quantitative analysis on multiple impurities in vitamin B1 raw materials, thus providing a reliable guarantee for better controlling the quality of vitamin B1 preparation products. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] Figure 1 This is the result of the ChP2020 impurity detection method optimized in Example 1 of the present invention.
[0035] Figure 2 This is the result obtained by the BP2021 / EP10.5 impurity detection method according to Example 2 of the present invention.
[0036] Figure 3 This is the result of detecting the impurity mixed solution using the optimized method 1 of the present invention.
[0037] Figure 4 This is the result of detecting the impurity mixed solution using the optimized method 2 of the present invention.
[0038] Figure 5 This is the result of detecting the impurity mixed solution using the optimized method 3 of the present invention.
[0039] Figure 6 This is the result of detecting the impurity mixed solution using the optimized method 4 of the present invention.
[0040] Figure 7 This is the result of detecting the impurity mixed solution using the optimized method 5 of the present invention.
[0041] Figure 8 This is the result of detecting the impurity mixed solution using the optimized method 6 of the present invention.
[0042] Fig. 9 This is the result of detecting the impurity mixed solution using the optimized method 7 of the present invention.
[0043] Fig.10 This is the result of detecting the impurity mixed solution using the optimized method 8 of the present invention. DETAILED DESCRIPTION
[0044] In order to make the purpose, technical solution and beneficial technical effect of the present invention clearer, the present invention is further described in detail below in conjunction with specific implementation methods. It should be understood that the specific implementation methods described in this specification are only for explaining the present invention, not for limiting the present invention.
[0045] The present invention provides a method for detecting vitamin B1-related impurities, comprising the following steps:
[0046] The sample to be tested is subjected to high performance liquid chromatography detection to obtain the impurity content related to vitamin B1; the conditions of the high performance liquid chromatography detection include: the chromatographic column is an octadecylsilane bonded silica gel column; the UV detector wavelength is 243nm~249nm; the column temperature is 25℃~50℃; the mobile phase flow rate is 0.7~1.3mL / min; the injection volume is 10~50μL; the mobile phase includes mobile phase A and mobile phase B, mobile phase A is hexane sulfonate solution; mobile phase B is methanol solution; the elution method is gradient elution; the diluent is a mixed solution of mobile phase A-mobile phase B.
[0047] In the present invention, the vitamin B1 related impurities include one or more of impurities A to L, impurity P, impurity N and o-chloroaniline; the names, structural formulas and sources of the above-mentioned impurities in the pharmacopoeia are shown in Table 1.
[0048] Table 1: Name, structural formula and source of vitamin B1 impurities
[0049]
[0050]
[0051] The present invention has no special requirements for the sample to be tested. Any sample that needs to be tested for vitamin B1 related impurities can be tested using the method of the present invention. In a specific embodiment of the present invention, the sample to be tested can be prepared from vitamin B1 bulk drug, vitamin B1 tablets, vitamin B1 capsules or vitamin B1 injection.
[0052] Specifically, when vitamin B1 raw materials are used to prepare the test sample, it is preferably prepared by the following method: Take 10 mg of the test sample, accurately weigh it, put it in a 10 ml volumetric flask, add a solvent to dissolve and dilute to the scale, shake well, and use it as the test sample solution.
[0053] When vitamin B1 tablets are used to prepare the sample to be tested, it is preferably prepared by the following method: take an appropriate amount of vitamin B1 tablet fine powder (equivalent to 50 mg of vitamin B1), accurately weigh it, put it in a 50 ml volumetric flask, add solvent to dissolve and dilute to the scale, shake well, filter, and take the filtrate as the test solution.
[0054] When vitamin B1 injection is used to prepare the sample to be tested, it is preferably prepared by the following method: accurately measure an appropriate amount of vitamin B1 injection (equivalent to 50 mg of vitamin B1), accurately weigh it, place it in a 50 ml volumetric flask, add solvent to dissolve and dilute to the scale, shake well, and use it as the test solution.
[0055] The solvents used for dissolving the sample and diluting the sample are the diluents described in the above chromatographic conditions.
[0056] In the present invention, the concentration of vitamin B1 in the sample to be tested is preferably 0.1-5 mg / mL, more preferably 1 mg / mL.
[0057] After obtaining the sample to be tested, the present invention performs high performance liquid chromatography detection on the sample to be tested to obtain the content of vitamin B1 related impurities. In the present invention, the conditions of the high performance liquid chromatography detection include:
[0058] The chromatographic column is an octadecylsilane bonded silica gel column; the model of the chromatographic column is preferably Kromasil KR100-5-C18, the size is preferably 4.6 mm (inner diameter) × 250 mm (column length), 3 μm or 5 μm (particle size);
[0059] The UV detector wavelength is 243nm to 249nm, preferably 245nm;
[0060] The column temperature is 25°C to 50°C, preferably 40°C to 50°C, more preferably 45°C;
[0061] The flow rate of the mobile phase is 0.7 to 1.3 mL / min, preferably 0.9 to 1.1 mL / min, and more preferably 1.0 mL / min;
[0062] The injection volume is 10 to 50 μL, preferably 20 to 30 μL; more preferably 25 μL;
[0063] The mobile phase includes mobile phase A and mobile phase B, wherein the mobile phase A is a hexane sulfonate solution, and the mobile phase B is methanol. The hexane sulfonate solution in the mobile phase A preferably contains a solution of hexane sulfonate ions, phosphate ions, amino ions and alkali metal ions; the alkali metal ions are preferably sodium ions. Specifically, the solute of the hexane sulfonate solution preferably includes sodium hexane sulfonate, phosphoric acid and triethylamine. The concentration of the sodium hexane sulfonate is preferably 1.882-5.647 g / L (0.01-0.03 mol / L), and more preferably 3.764 g / L (0.02 mol / L). The concentration of triethylamine is preferably 0.1%-1.0%, and more preferably 0.8%. The concentration of phosphoric acid is based on adjusting the pH value of the hexane sulfonate solution to 3.2. In a specific embodiment of the present invention, the concentration of sodium hexane sulfonate in the hexane sulfonate is 3.764 g / L, and the concentration of triethylamine is 0.8%. In a specific embodiment of the present invention, 3.764 g of sodium hexanesulfonate and 0.8% triethylamine were dissolved in water and the volume was fixed to 1000 mL, and then phosphoric acid was used to adjust the pH to 3.2 to obtain the hexanesulfonate solution.
[0064] The elution method is gradient elution. In the present invention, in the gradient elution process, the volume fractions of the three phases of phosphate buffer, acetonitrile and methanol are preferably as shown in Table 2 based on the total volume of mobile phase A and mobile phase B.
[0065] Table 2: Volume fractions of hexanesulfonate and methanol during gradient elution
[0066]
[0067] The procedure of the gradient elution is preferably as shown in Table 3.
[0068] Table 3: Volume fractions of hexanesulfonate and methanol during gradient elution
[0069]
[0070] The diluent is a mixed solution of mobile phase A-mobile phase B; the mobile phase A in the mixed solution of mobile phase A-mobile phase B is a hexane sulfonate solution, and the solutes in the hexane sulfonate solution are preferably sodium hexane sulfonate, phosphoric acid and triethylamine; the concentration of each solute in the hexane sulfonate is preferably consistent with the concentration of the hexane sulfonate solute in the mobile phase A, which will not be repeated here. In a specific embodiment of the present invention, it is preferred to dissolve 3.764g of sodium hexane sulfonate and 0.8% triethylamine and then dilute to 1000mL, adjust the pH to 3.2 with phosphoric acid, and obtain the hexane sulfonate solution, and then mix it with methanol in a volume ratio of (95:5) to obtain the solvent. The present invention uses the above-mentioned diluent to dissolve the sample, and the composition of the diluent is close to that of the mobile phase, which can reduce the peak shape abnormality or baseline fluctuation caused by the solvent effect.
[0071] The sample to be tested is subjected to high performance liquid chromatography according to the above conditions to obtain a high performance liquid chromatogram, and the content of each relevant impurity is calculated according to the chromatogram. In a specific embodiment of the present invention, it is preferred to first prepare a standard solution of each relevant impurity, and then perform high performance liquid chromatography according to the above detection conditions. The separated relevant substances are qualitatively analyzed according to the retention time of the standard in the high performance liquid chromatogram and the retention time of the sample to be tested in the high performance liquid chromatogram. The relevant impurities in the sample to be tested can be quantified according to the peak area of the standard in the high performance liquid chromatogram, the concentration of the standard and the peak area of the sample to be tested in the high performance liquid chromatogram. The present invention has no special requirements for the specific calculation method, and the calculation can be performed according to the method well known to those skilled in the art.
[0072] The technical scheme of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention, and the reagents involved are all commercially available products.
[0073] Example 1
[0074] Referring to the relevant method of vitamin B1 tablets, since the retention time of impurity H was too long, the impurities related to ChP2020 could not be effectively eluted. The method for the impurities related to ChP2020 was gradient optimized, and the optimized method is shown in Table 4.
[0075] Table 4: Optimized ChP2020 related impurity detection method
[0076]
[0077]
[0078] Raw material test solution: Take about 10 mg of vitamin B1 raw material, accurately weigh it, put it in a 10 ml volumetric flask, add an appropriate amount of mobile phase A, shake to dissolve the vitamin B1, dilute it to the scale with mobile phase A, shake well, and use it as the raw material test solution.
[0079] Impurity reference substance stock solution: Take appropriate amount of impurity A, impurity B, impurity C, impurity D, impurity E, impurity F, impurity G, impurity H, o-chloroaniline and disulfide (impurity L) reference substances, accurately weigh them, add mobile phase A to dissolve them respectively and quantitatively dilute them to make a solution containing 0.5 mg / ml as the impurity reference substance stock solution.
[0080] Impurity localization solution (1): Accurately measure appropriate amounts of impurity A, impurity B, impurity C, impurity D, impurity E, impurity F, impurity G, impurity H, o-chloroaniline and disulfide (impurity L) reference substance stock solutions, and quantitatively dilute them with mobile phase A to prepare a solution containing 0.05 mg / ml, which is used as the impurity localization solution (1).
[0081] Impurity mixed solution (1): Take about 25 mg of vitamin B1 raw material, weigh accurately, put into a 25 ml volumetric flask, accurately add 1 ml of each impurity location solution, dilute to the scale with mobile phase A, shake well, and use this as the impurity mixed solution (1).
[0082] According to the above chromatographic conditions, accurately measure 20 μl of each of blank solvent, API test solution, impurity localization solution (1) and impurity mixed solution (1), inject them into the liquid chromatograph respectively, and record the chromatogram.
[0083] The results are shown in Table 5. Figure 1 shown.
[0084] Table 5: Reproducible results of the optimized ChP2020 impurity detection method
[0085]
[0086] The results show that the blank solvent does not interfere with the detection of related impurities. The peak order is impurity A, impurity B, vitamin B1, impurity D, disulfide (impurity L), impurity F, impurity G, impurity E, impurity C, impurity H and o-chloroaniline, but the peak shape of disulfide (impurity L) is poor, which is a shoulder peak. In the mixed solution, the separation between impurities and the main component and between impurities is greater than 1.5, and the separation is good, but disulfide (impurity L) does not peak. The theoretical plate number is calculated based on the vitamin B1 peak and is greater than 2000.
[0087] In the later stage, impurities 1 to 3, thiochrome (impurity N) and carboxamidomethylpyrimidine (impurity P) were located, and the results are shown in Table 6.
[0088] Table 6: Impurity location results of the optimized ChP2020 impurity detection method
[0089]
[0090] The results showed that they were all concentrated in front of the main peak, and multiple impurities overlapped with each other.
[0091] Example 2
[0092] The method for related substances of BP2021 / EP10.5 was reproduced, and the liquid chromatography conditions are shown in Table 7.
[0093] Table 7: Chromatographic conditions of EP10.5 related substances method
[0094]
[0095] Impurity reference substance stock solution: Take appropriate amount of impurity A, impurity B, impurity C, impurity D, impurity E, impurity F, impurity G, impurity H, o-chloroaniline and disulfide (impurity L) reference substances, accurately weigh them, add optimized ChP2020 mobile phase A to dissolve and quantitatively dilute to make a solution containing 0.5 mg / ml as the impurity reference substance stock solution.
[0096] Impurity localization solution (1): Accurately measure appropriate amounts of impurity A, impurity B, impurity C, impurity D, impurity E, impurity F, impurity G, impurity H, o-chloroaniline and disulfide (impurity L) reference substance stock solutions, and quantitatively dilute them with optimized ChP2020 mobile phase A to prepare a solution containing 0.05 mg / ml, as the impurity localization solution (1).
[0097] Impurity 1 reference substance stock solution: Take an appropriate amount of impurity 1 reference substance, weigh it accurately, add the optimized ChP2020 mobile phase A to dissolve it and quantitatively dilute it to make a solution containing 2 mg / ml as the impurity 1 reference substance stock solution.
[0098] Impurity 2 reference substance stock solution: Take an appropriate amount of impurity 2 reference substance, weigh it accurately, add the optimized ChP2020 mobile phase A to dissolve it and quantitatively dilute it to make a solution containing 1 mg / ml as the impurity 2 reference substance stock solution.
[0099] Impurity 3 reference substance stock solution: Take an appropriate amount of impurity 3 reference substance, weigh it accurately, add the optimized ChP2020 mobile phase A to dissolve it and quantitatively dilute it to make a solution containing 1 mg / ml as the impurity 3 reference substance stock solution.
[0100] Thiochrome (Impurity N) reference substance stock solution: Take an appropriate amount of thiochrome (impurity N) reference substance, accurately weigh it, add the optimized ChP2020 mobile phase A to dissolve it and quantitatively dilute it to make a solution containing 1 mg / ml as the thiochrome (impurity N) reference substance stock solution.
[0101] Impurity localization solution (2): Accurately measure appropriate amounts of impurity 1, impurity 2, impurity 3 and thiochrome (impurity N) reference stock solutions, and quantitatively dilute them with optimized ChP2020 mobile phase A to prepare a solution containing 0.05 mg / ml as the impurity localization solution (2).
[0102] Formamidomethylpyrimidine (impurity P) reference standard solution: Take an appropriate amount of formamidomethylpyrimidine (impurity P) reference, accurately weigh it, add the optimized ChP2020 mobile phase A to dissolve it and quantitatively dilute it to make a solution containing 0.1 mg / ml as the formamidomethylpyrimidine (impurity P) reference standard stock solution.
[0103] Impurity mixed solution (2): Take about 25 mg of vitamin B1 raw material, weigh accurately, put into a 25 ml volumetric flask, accurately add 1 ml of each impurity location solution, dilute to the scale with optimized ChP2020 mobile phase A, shake well, and use this as the impurity mixed solution (2).
[0104] According to the above-mentioned liquid chromatography conditions, 25 μl of each impurity localization solution and impurity mixed solution (2) were accurately measured and injected into the liquid chromatograph to record the chromatogram to examine the impurity separation.
[0105] The results are shown in Table 8. Figure 2 shown.
[0106] Table 8: Reproducible results of impurity detection methods in BP2021 / EP10.5
[0107]
[0108]
[0109] The results show that the blank solvent does not interfere with the detection of impurities. The peak order is impurity A, impurity 2, formamidomethylpyrimidine (impurity P), impurity 1, thiochrome (impurity N), impurity D, impurity B, impurity E, vitamin B1, impurity 3, o-chloroaniline, disulfide (impurity L), impurity F, impurity G, impurity C and impurity H, but the peak shape of impurity A is poor, which is a shoulder peak. In the mixed solution, impurity 3 overlaps with the main component, and the impurities after the main peak are densely distributed, and the separation does not meet the requirements. The method is not suitable, so it is proposed to establish a detection method for impurities in raw materials based on the EP10.5 method.
[0110] Example 3
[0111] By reducing the elution rate of the organic phase, the gradient of the EP-related impurity detection method was optimized. The optimized method is shown in Table 9.
[0112] Table 9: Impurity Optimization Method 1
[0113]
[0114] According to the above-mentioned liquid chromatography conditions, accurately measure 25 μl of the impurity mixed solution (2), inject it into the liquid chromatograph, and record the chromatogram to examine the impurity separation.
[0115] The results are shown in Table 10. Figure 3 shown.
[0116] Table 10: Results of impurity optimization method 1 - impurity mixed solution
[0117]
[0118] The results showed that the separation degree between impurity 3 and the main peak was insufficient, disulfide (impurity L) overlapped with impurity F, and the impurities after the main peak were densely distributed and there was no improvement. Continue to try to adjust the elution gradient.
[0119] Example 4
[0120] By reducing the elution rate of the organic phase, the gradient of Optimization Example 3 was optimized, and the optimized method is shown in Table 11.
[0121] Table 11: Impurity detection optimization method 2
[0122]
[0123] Impurity mixed solution (3): Take about 25 mg of vitamin B1 raw material, weigh accurately, put it in a 25 ml volumetric flask, accurately add disulfide (impurity L) impurity localization solution (0.05 mg / ml) 2 ml, formamidomethyl pyrimidine (impurity P) impurity localization solution (100 μg / ml) 1 ml, o-chloroaniline stock solution (0.5 mg / ml) 2 ml, and 1 ml of the remaining impurity localization solutions, dilute to the scale with optimized ChP2020 mobile phase A, shake well, and use as impurity mixed solution (3).
[0124] According to the above-mentioned liquid chromatography conditions, accurately measure 25 μl of the impurity mixed solution (3), inject it into the liquid chromatograph, and record the chromatogram to examine the impurity separation.
[0125] The results are shown in Table 12. Figure 4 shown.
[0126] Table 12: Results of impurity detection optimization method 2 - impurity mixed solution
[0127]
[0128]
[0129] *Note: The largest single impurity refers to the impurity with the largest content among the unknown impurities of the relevant substance (the same below).
[0130] The results show that impurity 3 overlaps with the main peak, and the separation degree of disulfide (impurity L) and impurity F does not meet the requirements. The main peak retention time of this method is 54 minutes, and the total analysis time is 105 minutes. It is still impossible to achieve the required separation degree of each impurity, and it is planned to try to adjust the pH value of the aqueous phase.
[0131] Example 5
[0132] The optimization was performed by adjusting the pH of the aqueous phase to 3.2. The optimized method is shown in Table 13.
[0133] Table 13: Impurity detection optimization method 3
[0134]
[0135]
[0136] According to the above-mentioned liquid chromatography conditions, accurately measure 25 μl of the impurity mixed solution (3), inject it into the liquid chromatograph, and record the chromatogram to examine the impurity separation.
[0137] The results are shown in Table 14. Figure 5 shown.
[0138] Table 14: Results of impurity detection optimization method 3 - impurity mixed solution
[0139]
[0140]
[0141] The results showed that impurity 3 overlapped with the main peak, and the separation of other impurities was not improved.
[0142] Based on the EP related substance method, the pH was adjusted to 2.1-3.6. The results showed that as the pH increased, impurity B moved forward, o-chloroaniline moved backward, the separation of impurity F and disulfide (impurity L) improved, the relative retention time and separation of other impurities were the same, and the overlap of impurity 3 with the main peak was not improved; when the pH decreased and the pH was not greater than 2.5, the peak shapes of impurities A, impurity 2, and methylaminopyrimidine (impurity P) were poor, the separation of each peak could not meet the requirements, and the method had poor durability. In the process of adjusting the gradient and pH, although baseline separation could be achieved between impurity 2, methylaminopyrimidine (impurity P), and impurity 1, the peak shape was poor, resulting in separation that did not meet the requirements. Try adding triethylamine to the aqueous phase.
[0143] Example 6
[0144] 0.1% triethylamine was added to the aqueous phase, and the optimized method is shown in Table 15.
[0145] Table 15: Impurity detection optimization method 4
[0146]
[0147]
[0148] According to the above-mentioned liquid chromatography conditions, accurately measure 25 μl of the impurity mixed solution (3), inject it into the liquid chromatograph, and record the chromatogram to examine the impurity separation.
[0149] The results are shown in Table 16. Figure 6 shown.
[0150] Table 16: Results of impurity detection optimization method 4 - impurity mixed solution
[0151]
[0152]
[0153] The results show that the peak shapes of impurities A, 2 and formamide are poor, the separation between impurities E, 3 and the main peak does not meet the requirements, the separation between disulfide (impurity L) and impurity G does not meet the requirements, but impurity 3 has a tendency to separate from the main peak. It is proposed to increase the concentration of triethylamine to 0.5%.
[0154] Example 7
[0155] 0.5% triethylamine was added to the aqueous phase, and the optimized method is shown in Table 17.
[0156] Table 17: Impurity detection optimization method 5
[0157]
[0158] According to the above-mentioned liquid chromatography conditions, accurately measure 25 μl of the impurity mixed solution (3), inject it into the liquid chromatograph, and record the chromatogram to examine the impurity separation.
[0159] The results are shown in Table 18. Figure 7 shown.
[0160] Table 18: Results of impurity detection optimization method 5 - impurity mixed solution
[0161]
[0162]
[0163] The results showed that the peak shapes of impurities A, 2 and formamide were greatly improved by increasing the concentration of triethylamine, with the retention time of the main peak moving forward, impurities D, E and o-chloroaniline moving backward, and impurity 3 moving forward. The concentration of triethylamine was further increased to 0.7%.
[0164] Example 8
[0165] 0.7% triethylamine was added to the aqueous phase and the elution gradient was adjusted. The optimized method is shown in Table 19.
[0166] Table 19: Impurity detection optimization method 6
[0167]
[0168] According to the above liquid chromatography conditions, accurately measure 25 μl of the impurity mixed solution (3), inject it into the liquid chromatograph, and record the chromatogram. Investigate the impurity separation. The results are shown in
[0169] Table 20, Figure 8 shown.
[0170] Table 20: Results of impurity detection optimization method 6 - impurity mixed solution
[0171]
[0172]
[0173] The results showed that the separation degree between sulfur pigment (impurity N) and impurity 3 was 2.799, but impurity E and impurity F overlapped, and the separation degrees of other components were good.
[0174] During the method exploration, it was found that the elution rate of the organic phase slowed down, the separation of impurity 2 and formamide was improved, but the separation of thiochrome (impurity N) and impurity 3 decreased, the retention time of impurity E shifted backward, and the separation or relative retention time of other impurities did not change significantly. However, the components could not be effectively separated, and the pH value was adjusted to 3.1.
[0175] Example 9
[0176] Adjust the elution gradient and adjust the pH value to 3.1. The optimized method is as follows
[0177] As shown in Table 21.
[0178] Table 21: Impurity detection optimization method 7
[0179]
[0180]
[0181] According to the above liquid chromatography conditions, 25 μl of the impurity mixed solution (3) was accurately measured and injected into the liquid chromatograph to record the chromatogram. The impurity separation was investigated. The results are shown in Table 22. Fig. 9 shown.
[0182] Table 22: Results of impurity detection optimization method 7 - impurity mixed solution
[0183]
[0184]
[0185] The results showed that impurity C and o-chloroaniline overlapped, and the other components were well separated.
[0186] This method was used for preliminary degradation, and the results are shown in Table 23.
[0187] Table 23: Results of impurity detection optimization method 7 - preliminary degradation results
[0188]
[0189]
[0190] The results showed that no thiochrome (impurity N) was degraded from the API and under various degradation conditions. No thiochrome (impurity N) was detected when the maximum absorption wavelength of thiochrome (impurity N) was 391 nm. Therefore, the thiochrome (impurity N) in the API was not controlled by the liquid phase method. Referring to the quality standard of USP42 vitamin B1, the ultraviolet-visible spectrophotometry was used to detect the absorbance at 400 nm to control the thiochrome (impurity N).
[0191] Example 10
[0192] The elution gradient was adjusted, the triethylamine concentration was increased to 0.8%, and the pH value was adjusted to 3.2. The optimized method is shown in Table 24.
[0193] Table 24: Impurity detection optimization method 8
[0194]
[0195] Impurity mixed solution (4): Take about 25 mg of vitamin B1 raw material, weigh accurately, put it in a 25 ml volumetric flask, accurately add disulfide (impurity L) impurity positioning solution (0.05 mg / ml) 2 ml, formamidomethyl pyrimidine (impurity P) impurity positioning solution (100 μg / ml) 1 ml, o-chloroaniline stock solution (0.5 mg / ml) 2 ml, impurity A~H positioning solution (0.05 mg / ml), impurity 1~3 1 ml each, dilute to the scale with mobile phase A-mobile phase B = 95:5, shake well, and use as impurity mixed solution (4).
[0196] According to the above liquid chromatography conditions, 25 μl of the impurity mixed solution (4) was accurately measured and injected into the liquid chromatograph to record the chromatogram. The impurity separation was investigated. The results are shown in Table 25. Fig.10 shown.
[0197] Table 25: Results of impurity detection optimization method 8 - impurity mixed solution
[0198]
[0199] The results showed that in the impurity mixed solution, the peak order of each component was impurity A, impurity 2, formamide methyl pyrimidine (impurity P), impurity 1, impurity B, impurity 3, the largest single impurity, vitamin B1, impurity D, impurity F, impurity E, impurity G, disulfide (impurity L), impurity C, o-chloroaniline and impurity H. The separation between impurities and the main component and between impurities was greater than 1.5, and the separation was good. When the concentration of each impurity was equivalent to 2% of the test sample concentration, the S / N was greater than 10 times the quantitative limit, and the sensitivity of the method met the requirements. Based on the maximum ultraviolet absorption wavelength of each impurity, the detection wavelength was set to 245nm.
[0200] It can be seen from the above embodiments that the detection method provided by the present invention realizes the detection of known and unknown impurities of vitamin B1 by one method, and the separation effect of each impurity is better than the methods in the Pharmacopoeia ChP2020 and BP2021 / EP10.5, and can achieve effective separation between impurities and between impurities and main peaks, and it is easier to obtain good peak shape and separation.
[0201] The above-mentioned reference specific implementation method has been described in detail for the detection method of vitamin B1 related impurities, but the description of the implementation example is illustrative rather than restrictive, and several embodiments can be listed according to the limited scope. Therefore, changes and optimizations without departing from the essence and scope of the technology of the present invention should be within the scope of protection of the present invention.
Claims
1. A method for detecting vitamin B1 impurities, characterized in that: The sample to be tested is subjected to high performance liquid chromatography detection, and the conditions include: the chromatographic column is an octadecylsilane bonded silica gel column; the UV detector wavelength is 245nm; the column temperature is 25℃~50℃; the mobile phase flow rate is 0.7~1.3mL / min; the injection volume is 10~50μL; the mobile phase includes mobile phase A and mobile phase B, mobile phase A is a hexane sulfonate solution; mobile phase B is a methanol solution; the elution method is gradient elution; the diluent is a mixed solution of mobile phase A-mobile phase B; The impurities are impurity A, impurity 2, impurity P, impurity 1, impurity B, impurity 3, impurity D, impurity F, impurity E, impurity G, impurity L, impurity C, o-chloroaniline and impurity H, and the structural formulas are: 、 、 、 、 、 、 、 、 、 、 、 、 、 ; The hexane sulfonate solution comprises sodium hexane sulfonate, triethylamine and phosphoric acid; the concentration of the sodium hexane sulfonate is 0.01-0.03 mol / L, the concentration of the triethylamine is 0.1%-1.0%, and the pH value of the hexane sulfonate solution is 3.2; The chromatographic column is of Kromasil KR100-5-C18 model, with a size of 4.6 mm × 250 mm and a particle size of 3 μm or 5 μm; During the gradient elution, based on the total volume of mobile phase A and mobile phase B, the volume fractions of the hexane sulfonate solution and methanol are: 0~20min: hexane sulfonate 95~99%, methanol 1~5%; 20-50min: hexane sulfonate 88-92%, methanol 8-12%; 50~70min: hexane sulfonate 73~77%, methanol 23~27%; 70-80min: hexane sulfonate 48-52%, methanol 48-52%; 80-80.1min: hexane sulfonate 48-52%, methanol 48-52%; 80.1~105min: hexane sulfonate 95~99%, methanol 1~5%; Above 105min: Hexane sulfonate 95~99%, methanol 1~5%.
2. The detection method according to claim 1, characterized in that: The procedure of the gradient elution is: 0~20min: mobile phase A 97%, mobile phase B 3%; 20-50min: mobile phase A 90%, mobile phase B 10%; 50-70min: mobile phase A 75%, mobile phase B 25%; 70-80min: mobile phase A 50%, mobile phase B 50%; 80-80.1min: mobile phase A 50%, mobile phase B 50%; 80.1-105min: mobile phase A 97%, mobile phase B 3%; More than 105 min: Mobile phase A 97%, mobile phase B 3%.
